Recalculating Risk vs. Opportunity in China Deal-Making

According to GBI-Healthcare data, Chinese biotechs entered into 46 out-licensing deals and 160 in-licensing deals with US or EU biopharma companies between January 2020 and May 2022.  China remains strategically important for biopharma deal-making with its predicted growth and market size, projected with a current CAGR of appx 7%.  However, the business environment continues to shift due to geopolitical tensions and macroeconomic and policy changes.  This session reviews the key questions every biopharma company should consider to mitigate against risk and capture value when assessing cross-pacific deals.